Ohio State Cancer Expert Joins HemOnc Today Editorial Board

November 18, 2011
Ohio State Cancer Expert Joins HemOnc Today Editorial Board Bekiai Saab

COLUMBUS, Ohio – Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), has been selected to be a member of the editorial board for HemOnc Today, a bimonthly global publication that provides timely and authoritative reports on clinical issues, socioeconomic topics and industry developments and other relevant information for oncology and hematology professionals.

Bekaii-Saab specializes in experimental agents for gastrointestinal malignancies including pancreatic, liver and colon cancers. An associate professor of medicine in the OSUCCC-James and Pharmacology in Ohio State's College of Medicine, he is a leader of the college's disease specific research group for gastrointestinal oncology.

Bekaii-Saab leads an active clinical research program including a novel, two-arm randomized phase II pancreas cancer clinical trial at Ohio State's Comprehensive Cancer Center that will study a formulation of the human reovirus, Reolysin that is designed to kill cancer cells.

Expected to enroll approximately 70 patients with pancreatic cancer, both at Ohio State and at other institutions, the study will compare the effects of two courses of treatment. One group of patients will receive the chemotherapy drugs carboplatin and paclitaxel. The other group will receive the two medications plus Reolysin, an engineered version of the human reovirus developed by Oncolytics Biotech Inc. of Calgary.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Click here for a high-quality photograph of Dr. Tanios Bekaii-Saab.

Contact: Gretchen Sauer, Medical Center Public Affairs and Media Relations, 614-293-3737, or Gretchen.Sauer@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

New Clinical Trial Aims to Reprogram Cells to Attack a Specific Relapsed Blood Cancer

An upcoming clinical trial at The James aims to reprogram a patient’s immune cells to attack a specific relapsed blood cancer, called multiple myeloma. The idea is to “super-charge” the patient’s immune...

Read More

NCCN Publishes New Guidelines for Smoking Cessation, Effort Led by Ohio State Oncologist

To meet the needs of patients who are smokers at the time of a cancer diagnosis, the National Comprehensive Cancer Network has published smoking cessation guidelines. Ohio State's Peter Shields, MD...

Read More

Molecules in Prostate Tumors Might Predict Whether RT Can Help Prevent Recurrence

A new study has identified a group of molecules in prostate-cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels...

Read More